FDA approves new DNA-based test to determine blood compatibility
date:Oct 12, 2018
s can be important when matching blood for transfusions since some people develop antibodies to non-ABO antigens. People who receive repeated blood transfusions, such as individuals with sickle cell disease, are more likely to develop these antibodies. If red blood cells with poorly matched non-ABO antigens are transfused, red blood cell destruction and a transfusion reaction can occur in a transfusion recipient.

Traditionally, red blood cell antigens have been identified using serological meth
3/5 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/11 03:31